UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2025



P3 Health Partners Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) **001-40033** (Commission File Number)

89074

85-2992794

(I.R.S. Employer Identification No.)

(Zip Code)

2370 Corporate Circle Suite 300 Henderson, Nevada (Address of principal executive offices)

cutive offices)

(702) 910-3950 (Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.0001 per share	PIII	The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of \$11.50	РШИ	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Art.

Item 2.02 Results of Operations and Financial Condition.

On March 27, 2025, P3 Health Partners Inc. (the "Company") announced its financial results for the fiscal year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Report").

The information in this Item 2.02, including the information contained in Exhibit 99.1 of this Report, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release of the Company, dated March 27, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

P3 Health Partners Inc.

Date: March 27, 2025

By: /s/ Leif Pedersen

Leif Pedersen Chief Financial Officer

P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results

Revenue increased 18% year-over-year to \$1.50 billion

Affirming 2025 guidance

Management to Host Conference Call and Webcast March 27, 2025 at 4:30 PM ET

HENDERSON, NV—March 27, 2025—P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance.

"Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention," said Aric Coffman, CEO of P3. "With the \$130M+ in identified programmatic opportunities advancing our path to financial sustainability, we remain committed to enabling our payor and provider partners to drive high quality, cost-efficient care and long-term market growth."

Fourth Quarter 2024 Financial Results

- Total revenue was \$370.7 million, an increase of 7% compared to \$346.9 million in the fourth quarter of the prior year
- · Capitated revenue was \$367.5 million, an increase of 7% compared to \$342.8 million in the fourth quarter of the prior year
- Gross profit was a loss of \$39.5 million, as compared to negative \$20.8 million in the fourth quarter of the prior year. Gross profit PMPM was a loss of \$103, as compared to a loss of \$65 in the fourth quarter of the prior year
- Medical margin⁽¹⁾ was \$7.3 million compared to \$9.1 million in the prior year. Medical margin PMPM⁽¹⁾ was \$19 compared to a medical margin PMPM of \$28 in the
 prior year
- Net loss was \$129.1 million compared to a net loss of \$69.1 million in the fourth quarter of the prior year. Net loss PMPM was \$335 compared to a net loss PMPM of \$220 in the prior year
- Adjusted EBITDA loss⁽¹⁾ was \$67.6 million compared to an Adjusted EBITDA loss¹⁾ of \$44.3 million in the fourth quarter of the prior year. Adjusted EBITDA loss PMPM⁽¹⁾ was \$175 compared to Adjusted EBITDA loss PMPM of \$138 in the fourth quarter of the prior year

Full-Year 2024 Financial Results

- At-risk membership of 123,800, an increase of approximately 14% compared to 108,900 in the prior yeaf²)
- Total revenue was \$1.50 billion, an increase of 18% compared to \$1.27 billion in the prior year
- Capitated revenue was \$1.48 billion, an increase of 18% compared to \$1.25 billion in the prior year
- Gross profit was a loss of \$58.9 million, as compared to positive \$31.6 million in the prior year. Gross profit PMPM was a loss of \$52, compared to a positive \$25 PMPM in the prior year
- Medical margin⁽¹⁾ was \$85.5 million, a decrease of 37% compared to \$135.1 million in the prior year. Medical margin PMPM¹⁾ was \$75, a decrease of 31% compared to a medical margin PMPM of \$108 in the prior year
- Net loss was \$310.4 million compared to a net loss of \$186.4 million in the prior year
- Adjusted EBITDA loss⁽¹⁾ was \$167.2 million compared to an Adjusted EBITDA loss⁽¹⁾ of \$85.5 million in the prior year. Adjusted EBITDA loss PMPM⁽¹⁾ was \$147 compared to Adjusted EBITDA loss PMPM⁽¹⁾ of \$68 in the prior year

Fiscal 2025 Guidance

	Year Ended Dec	ember 31, 2025
	Low	High
At-risk Members	109,000	119,000
Total Revenues (in millions)	\$1,350	\$1,500
Medical Margin ⁽¹⁾⁽³⁾ (in millions)	\$174	\$210
Medical Margin ⁽³⁾ PMPM	\$133	\$147
Adjusted EBITDA ⁽³⁾ (in millions)	\$(35)	\$5

(1) Adjusted EBITDA, Adjusted EBITDA per member, per month ("PMPM"), medical margin, and medical margin PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures, if applicable, and more information regarding the Company's use of non-GAAP financial measures, please see the section titled "Non-GAAP Financial Measures."

⁽²⁾ See "Key Performance Metrics" for additional information on how the Company defines "at-risk members."

(3) The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA, medical margin and medical margin PMPM to net income (loss), gross profit and gross profit PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss), because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) PMPM that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Non-GAAP Financial Measures" below.

The foregoing 2025 outlook statement represents management's current estimate as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the "Cautionary Note Regarding Forward-Looking Statements" included in this release. Management does not assume any obligation to update these estimates.

Management to Host Conference Call and Webcast on March 27, 2025 at 4:30 PM ET

Title & Webcast	P3 Health Fourth Quarter and Full Year 2024 Earnings Conference Call							
Date & Time	March 27, 2025, 4:30pm Eastern Time							
Conference Call Details	Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partners call							
The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the P3 website (r.p3hp.org). The Company's press release will								

be available at <u>ir.p3hp.org</u> website in advance of the conference call. An archived recording of the webcast will be available at<u>ir.p3hp.org</u> for a period of 90 days following the conference call.

About P3 Health Partners (NASDAQ: PIII):

<u>P3 Health Partners Inc.</u> is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 3,100 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 27 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient's care within the healthcare system. For more information, visit <u>www.p3hp.org</u> and follow us on @p3healthpartners and <u>Facebook.com/p3healthpartners</u>.

Non-GAAP Financial Measures

In addition to the financial results prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP"), this press release contains certain non-GAAP financial measures as defined by the SEC rules, including Adjusted EBITDA and Adjusted EBITDA PMPM, medical margin, and medical margin PMPM. EBITDA is defined as GAAP net income (loss) before (i) interest, (ii) income taxes and (iii) depreciation and amortization. Adjusted EBITDA is

defined as EBITDA, further adjusted to exclude the effect of certain supplemental adjustments, such as (i) mark-to-market warrant gain/loss, (ii) premium deficiency reserves, (iii) equity-based compensation expense, (iv) certain transaction and other related costs and (v) certain other items that we believe are not indicative of our core operating performances. Adjusted EBITDA PMPM is defined as Adjusted EBITDA divided by the number of at-risk Medicare members each month divided by the number of months in the period. We believe these non-GAAP financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other similar companies. Medical margin represents the amount earned from capitation revenue after medical claims expenses are deducted and medical margin PMPM is defined as medical margin divided by the number of Medicare members each month divided by the number of months in the period. Medical claims expenses represent costs incurred for medical services provided to our members. As our platform grows and matures over time, we expect medical margin to increase in absolute dollars; however, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We do not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In addition, other companies may calculate non-GAAP financial measures are used in the usefulness of our non-GAAP financial measures. The tables at the end of this press release present a reconciliation of Adjusted EBITDA to net income (loss) and Adjusted EBITDA PMPM to net income (loss)

Key Performance Metrics

In addition to our GAAP and non-GAAP financial information, the Company also monitors "at-risk members" to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. At-risk membership represents the approximate number of Medicare members for whom we receive a fixed percentage of premium under capitation arrangements as of the end of a particular period.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements address various matters, including the Company's future expected growth strategy and operating performance; and the Company's ability to execute on its identified strategic improvement opportunities, all of which reflect the Company's expectations based upon currently available information and data. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, our ability to continue as a going concern; our potential need to raise additional capital to fund our existing operations or develop and commercialize new services or expand our operations; our ability to achieve or maintain profitability; our ability to maintain compliance with our debt covenants in the future, or obtain required waivers from our lenders if future operating performance were to fall below current projections, and if there are material changes to management's assumptions, we could be required to recognize non-cash charges to operating earnings for goodwill and/or other intangible asset impairment; our ability to identify and develop successful new geographies, physician partners, payors and patients; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to fund our gravitors and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payors; the impact of fluctuations in risk adjustments; our ability to establish and maintain effective

internal controls and the impact of material weaknesses we have identified; our ability to maintain the listing of our securities on Nasdaq; increased labor costs and medical expense; our ability to recruit and retain qualified team members and independent physicians; and the factors described under Part I, Item 1A. "Risk Factors" and Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2024, and in our subsequent filings with the SEC.

All information in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. You are cautioned not to place undue reliance on any forward-looking statements contained in this press release.

Ryan Halsted Investor Relations Gilmartin Group ir@p3hp.org

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts) (unaudited)

Same Bestinder dataS38.80S3.302Fischied cases Internet and other neuroida121.266118.467Fischied cases regenes and other caret bases of 51914.422.0.633Pright cases and other caret bases of 51914.422.0.633Asseth def for sale.0.400.0.400TOTAL CURRENT ASSETS.1.84.400.0.6007Narphet de sign cases and objument, net set and comments.0.534.8.660.303Other Long clear mases.0.91.400.0.91.400Other Long clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.92.400Chases clear mases.0.91.400.0.92.400Chases clear mases.0.91.400.0.92.400Chases payable.0.92.400.0.82.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400 <t< th=""><th></th><th></th><th>December 31, 2024</th><th>December 31, 2023</th></t<>			December 31, 2024	December 31, 2023
Same Bestinder dataS38.80S3.302Fischied cases Internet and other neuroida121.266118.467Fischied cases regenes and other caret bases of 51914.422.0.633Pright cases and other caret bases of 51914.422.0.633Asseth def for sale.0.400.0.400TOTAL CURRENT ASSETS.1.84.400.0.6007Narphet de sign cases and objument, net set and comments.0.534.8.660.303Other Long clear mases.0.91.400.0.91.400Other Long clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.91.400Chases clear mases.0.91.400.0.92.400Chases clear mases.0.91.400.0.92.400Chases clear mases.0.91.400.0.92.400Chases payable.0.92.400.0.82.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400Chases payable.0.92.400.0.92.400 <t< th=""><th>ASSETS</th><th></th><th></th><th></th></t<>	ASSETS			
Besting lane scale5,864,614Health glane scale12,12,66118,497Cline fees, insurance and other rectivable, for of allosses of \$15013,4972973Payelia equences of other arceivable440Payelia equences and other arceivable14,4923.6313Assets hald for allo118,414160017Product CHRENT ASSETS184,440165017Product equences and other arceivable574,5438.666,733Other langebin assis19,19619,53116533Other langebin assis19,19619,53116533CURRENT LANDETTES58,46256,8633Accounte payelia2,52519,65319,65319,653Current Labilities29,6435,8643,663Accounte payelia2,525319,65319,65319,653Charlen payelia2,55317,85919,65319,653Current Labilities2,55317,85917,85919,65319,653Charlen payelia2,55317,85917,85911,59311,59311,593Charlen payelia2,55317,85917,85911,593 <t< td=""><td>CURRENT ASSETS:</td><td></td><td></td><td></td></t<>	CURRENT ASSETS:			
Ibelin plan receivable, net of allowane for codi lowase of \$150121,266114,4223613Propia degenes and obre receivable40344423613Propia degenes and obre receivable403154,140166,017Propie degenes and obre receivable574,550666,733161,650163,650Doter Lowgenes Ansets574,550666,733161,650163,650Doter Lowgenes Ansets574,550666,733163,650163,650CIRRENT LABLERTS\$74,540666,733163,650163,550CIRRENT LABLERTS\$74,54086,860,860163,550163,550163,550CIRRENT LABLERTS\$74,54056,864163,650163,550163,550163,550163,550CIRRENT LABLERTS\$74,54056,864163,650163,550	Cash	\$	38,816	\$ 36,320
Clinic pice, insurance and other receivable3.4472.731Prepaid expenses and other current ases400—DTAL CURRENT ASSETS188,140166.071Operty and equipment, net5.7346.666,731Oher long, erm assets10,14019.133TOTAL CURRENT ASSETS5360.667.13Oher long, erm assets10,14019.133TOTAL ASSETS5360.667.13Oher long, erm assets10,14019.133CURRENT LARGITITES.58.4425Concourts payable22.94136.854Accounds payable25.55534.9592Calling payable25.55534.9592Clains payable35.55534.9592Clains payable35.55534.9592Clains payable35.55534.9592Clains payable35.55534.9592Clains payable35.55534.9592 <td>Restricted cash</td> <td></td> <td>5,286</td> <td>4,614</td>	Restricted cash		5,286	4,614
pregia degeness and other current assets14.4223.611Assets held for sale403—TOTAL CURRENT ASSETS184.140166.077Property and equipment, net5.7348.686Imaghen assets, net191.98191.531Other long-term assets19.198191.531CURRENT LARDERSP878.2008CARCENT LARDERSP88.80.67CARCENT LARDERSP88.80.67CARCENT LARDERSP88.80.67CARCENT LARDERSP28.80.67CARCENT LARDERSP28.80.67CARCENT LARDERSP24.163.884CARCENT LARDERSP24.163.884CARCENT LARDERSP24.163.884CARCENT LARDERSP24.163.884CARCENT LARDERSP25.06917.8.09Lardent LIRDERSP25.06917.8.09Carcent diptroll25.06917.8.09Carcent diptroll25.06917.8.09Premium deficiency resere67.3813.670Carcent diptroll25.0917.8.09Contradt protion of long-term tabihities65.00Labihities Left for sale25.0917.8.09Contradt protion of long-term debt10.31210.82Contradt protion of long-term tabihities10.31210.82Contradt protion of long-term tabihities10.31210.82Contradt protion of long-term tabihities25.0910.83Contradt protion of long-term tabihities25.0910.83Contr	Health plan receivable, net of allowance for credit losses of \$150		121,266	118,497
Avers lad for ale403TOTAL CURRENT ASSTS184.100165.03165.03Pretry and equipment, net5.73.36.86.03169.13Direl langettin assts19.1619.13119.131TOTAL ASSTS37.83.205\$660.23TOTAL ASSTS57.83.205\$660.27LIBRILITES, WEZANINE EQUITY, AND STOCKHOLDERS' EQUITY	Clinic fees, insurance and other receivable		3,947	2,973
NOTAL CURRENT ASSETS 184.400 166.017 Property and quipment, net 5,734 8.666 Property and quipment, net 5,734 8.666 Other Inegierum assets 19,106 19,310 666,733 Other Inegierum assets 19,106 19,311 78,420 5 8660,733 LABELITIES, MEZZANIKE QUITY, AND STOCKHOLDERS' EQUITY 78,420 5 8660,733 78,920 79,920 78,920 78	Prepaid expenses and other current assets		14,422	3,613
Property and quipment, net1,7,148,686Imagible assets, net574,353666,733Other long-term assets19,16619,311TOTAL ASSETS ¹⁰ \$78,840\$860,067ILABLITTES. RZANNE REQUITY, AND STOCKHOLDERS EQUITY5CURRENT LIABLITTES29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Accroade approla29,416\$6,663Charting payable29,565\$1,43,092Charting payable25,565\$1,43,092Charting payable65,005Liabitios hold for sale65,000Liabitios hold for sale11,333\$1,352Correat portion of ong-term dole, net40,613299,372Contager consideration4,097Lang-term liabilities25,001Contager consideration4,097Lang-term liabities25,001Contager consideration4,097Lang-term liabities25,001Contager consideration4,097Lang-term liabities30,001Contager consi	Assets held for sale		403	—
InamyBile seets, net 574.350 666.733 Other long-term asets 19,106 19,501 ITAL ASSETS ⁰ \$ 783.200 \$ 800.967 LABEUTES, MEZZANDE EQUITY, AND STOCKHOLDERS' EQUITY \$ 783.200 \$ 800.967 CURRENT LIABUITIES. 29,416 36,663 Accrued payable 29,416 36,863 Accrued payable 27,22 3,506 Healti plan settlements payable 25,565 34,992 Claims payable 255,565 34,992 Premiun deficiency reserve 673,38 13,600 Claims payable 25,069 178,009 Current portion of long-term debt 65,000 Labilities held for sale 333 Current portion of long-term debt 65,000 Labilities held for sale 333 Contingent consideration 4,907 Deparating Helsen Hability 11,313 11,623 Contingent consideration 4,907 Deparating Helsen Hability 10,312 10,852	TOTAL CURRENT ASSETS		184,140	 166,017
Other long-term assets191,06191,301TOTA.A SASTES*\$ 193,402\$ 860,907LABLITTES. MEZANTNE EQUITY. AND STOCKHOLDERS' EQUITYCURRENTS \$ 842\$ 860,307Accounds expenses and other current liabilities294,1636,884Accrued expenses and other current liabilities294,1636,884Accrued expenses and other current liabilities55,5634,992Health plan settlements payable55,5634,992Chaires payable255,6831,860Perminu deficiency reserve67,36831,3670Current portion of long-term debt65,000Labilities held for sale65,000Labilities held for sale64,01329,9372Openting lease liability11,339Openting lease liability11,331Conting extern debt, nt4,907Conting extern debt, nt4,907Conting extern debt, nt4,907Dier Long-Term Liabilities4,907Conting extern debt, nt4,907Conting extern debt, nt4,907MEZZANINE EQUITY:4,907Class Voorm Books, S0000 part value; 200,000 shares authorized; 105,597 and 105,598 alares issued and outstanding as of December 31,2024 and 2023, respectively16Class Voorm Sock, S0000 part value; 200,000 shares authorized; 105,597 and 105,598 alares issued and outstanding as of December 31,2024 and 2023, respectively16Class Voorm Sock, S0000	Property and equipment, net		5,734	8,686
S 783,420 S 783,420 S 860,967 LABLITTES, MEZZANNE EQUITY, AND STOCKHOLDERS' EQUITY	Intangible assets, net		574,350	666,733
Difference S 8,442 S 8,663 Accounts payable 29,416 35,863 3,566 Accounts payable 29,416 35,865 3,4992 3,566 ItealitITES. 29,416 35,865 3,4992 3,566 ItealitITES. 25,565 34,992 1,3,506 1,360 1,362 1,360 1,362 1,362 1,362 1,863 1,362 1,863 1,362 1,863 1,362 1,863 1,862 1,863 1,862 1,863 1,862 1,863 1,862 1,863 1,862	Other long-term assets		19,196	19,531
CURRENT LIABILITIES: \$ 8,420 \$ 8,630 Accound payoll 29,416 \$ 0,683 Accound payoll 2,722 3,506 Chall phan stelements payable 55,565 \$ 34,992 Chall phan stelements payable 255,806 \$ 34,992 Chall phan stelements payable 255,806 \$ 34,992 Chall phan stelements payable 67,368 \$ 13,670 Accrued interst 67,368 \$ 35,367 Current portion of long-term debt 66,000 Liabilities held for sale 353 TOTAL CURRENT LIABILITIES 496,6415 299,372 Operating lase liability 11,333 13,622 Operating lase liability 11,333 13,622 Contigent consideration 490,613 Contigent consideration 49,824 Contigent consideration 49,824 Contigent consideration 49,824 Contegent consideration 49,907 Contegent consideration 49,907 <td>TOTAL ASSETS⁽¹⁾</td> <td>\$</td> <td>783,420</td> <td>\$ 860,967</td>	TOTAL ASSETS ⁽¹⁾	\$	783,420	\$ 860,967
Accounts payable S 8.442 S 8.663 Accrued expenses and other current liabilities 29,416 36,884 Accrued expenses and other current liabilities 27,722 3,506 Heath plan settlements payable 25,565 34,3992 Claims payable 25,565 34,3992 Claims payable 63,368 13,670 Accrued interest 12,460 22,5688 Current payrito folong-term debt 65,000 Liabilities held for sale 353 Operating lease liability 11,339 13,622 Quartant patholities 10,312 1,032 Contingent consideration 4,907 Operating lease liability 10,312 1,085 Contingent consideration 4,907 Contingent consideration 4,907 Conteng error liabilities 20,001 Contingent consideration 4,907 Conteng error liabilities 20,001 Contingent consideration	LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY			
Accrued expenses and other current liabilities 29,416 36,884 Accrued payroll 2,722 3,506 Health plan settlements payble 55,55 34,992 Chinns payable 255,089 178,009 Premium deficiency reserve 67,368 13,670 Accrued interest 12,460 235,309 Current portion of long-term debt 65,000 Liabilities held for sale 353 OTAL CURRENT LIABILITIES 406,615 299,372 Operating lease liability 11,339 13,622 Warnant liabilities 10,312 1,085 Contingert consideration - 4,907 Long-term debt, net 26,001 Other Long-term Liabilities 26,001 COMMITMENTS AND CONTINGENCIES (Note 13) - 42,7305 REZZANINE EQUITY: - 633,81 427,305 Class Voommon stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and oustanding as of December 31, 2024 and 2023, respectively 16 12 Class Voommon stock, \$0,0001 par	CURRENT LIABILITIES:			
Accured payroll 2,722 3,506 Health plan settlements pyable 55,565 174,809 Claims payable 67,368 13,670 Accrued interest 67,368 13,670 Current portion of long-term debt 65,000 - Liabilities held for sale 353 - TOTAL CURRENT LIABILITIES 496,615 299,372 Operating lease liability 11,339 13,622 Variant liabilities 10,112 1,082 Consing et consideration - 4,907 Long-term debt, net 89,824 108,319 Other Long-Term Liabilities 26,001 - Contingent consideration - 4,907 Long-term debt, net 89,824 108,319 Other Long-Term Liabilities 26,001 - COMMITMENTS AND CONTINGENCIES (Note 13) - - MEZZANINE EQUITY: - 427,305 Class A common stock, 50,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 <tr< td=""><td>Accounts payable</td><td>\$</td><td>8,442</td><td>\$ 8,663</td></tr<>	Accounts payable	\$	8,442	\$ 8,663
Health plan settlements payable 55,565 34,992 Claims payable 255,089 178,009 Premium deficiency reserve 67,368 13,360 Accrued interest 12,460 23,648 Current portion of long-term debt 65,000 — Liabilities held for sale 353 — TOTAL CURRENT LIABILITIES 496,415 299,372 Operating lease liability 11,339 13,522 Warrant liabilities 10,312 1,083 Contingent consideration — 49,007 Long-term debt, net 00,811 108,319 Other Long-Term Liabilities 26,001 — TOTAL LIABILITIES ⁴⁰ 633,891 427,305 COMMTMENTS AND CONTINGENCIES (Note 13) 533,891 427,305 REZZANNE COUTTY:	Accrued expenses and other current liabilities		29,416	36,884
Claims payable 255,089 178,009 Premium deficiency reserve 67,368 13,670 Accrucal interst 12,460 12,460 Current portion of long-term debt 65,000 — Liabilities held for sale 33 — TOTAL CURRENT LIABILITIES 496,415 299,372 Operating lease liability 11,339 13,622 Warmant liabilities 10,312 10,835 Conting consideration — 496,015 Conting-term Liabilities 88,824 108,319 Oher Long-Term Liabilities 26,001 — COMMTINETNS AND CONTINGENCIES (Note 13) 21,523 20,501 MEZZANINE EQUITY: Totak common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 10 12 Class A common stock, \$0,00001 par value; 205,000 shares authorized; 195,997 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 10 12 Class A common stock, \$0,00001 par value; 205,000 shares authorized; 195,997 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 10 10	Accrued payroll		2,722	3,506
Premium deficiency reserve 67,368 13,670 Accrued interest 12,460 23,648 Current portion of long-term debt 65,000 Liabilities held for sale 353 TOTAL CURRENT LIABILITIES 496,415 299,372 Operating lease liability 11,339 13,622 Warrant liabilities 10,312 1085 Contingent consideration 4,907 Long-term debt, net 89,824 108,319 Other Long-Term Liabilities 26,001 COMMITMENTS AND CONTINGENCIES (Note 13) 53,931 MEZZANINE EQUITY: 427,305 Redeemable non-controlling intrest 73,593 291,532 STOCKHOLDERS' EQUITY: 20 20 Class A common stock, \$0.0001 par value; 205,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class A common stock, \$0.0001 par value; 20,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Class A common	Health plan settlements payable		55,565	34,992
Accrued interest 12,460 23,648 Curret portion of long-term debt 65,000 — Liabilities held for sale 353 — TOTAL CURRENT LIABILITIES 496,415 299,372 Operating lease liability 11,339 13,622 Warrant liabilities 10,312 10,8319 Contingent consideration — 4,907 Long-term Liabilities 26,001 — Constident consideration 26,001 — TOTAL LIABILITIES ⁽¹⁾ 26,001 — COMMITENTS AND CONTINGENCIES (Note 13) — — MEZZANINE EQUITY: 73,593 291,532 COCKMOLDERS' EQUITY: — 20 Class A common stock, \$0,0001 par value; 800,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively	Claims payable		255,089	178,009
Current portion of long-term debt 65,000 — Liabilities held for sale 353 — TOTAL CURRENT LIABILITIES 496,415 299,372 Operating lease liability 10,312 1,085 Quarant liabilities 10,312 1,085 Contingent consideration — 4907 Long-term Liabilities 26,001 — TOTAL LIABILITIES ⁽¹⁾ 26,001 — COMMITMENTS AND CONTINGENCIES (Note 13) 427,305 201,532 MEZZANINE EQUITY: 633,891 427,305 Redeemable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: 16 12 Class A common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class A common stock, \$0,0001 par value; 205,000 shares authorized; 162,670 and 116,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class A common stock, \$0,0001 par value; 205,000 shares authorized; 162,670 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class A common stoc	Premium deficiency reserve		67,368	13,670
Liabilities held for sale 353 — TOTA L CURRENT LIABILITIES 496,415 299,372 Operating lease liability 10,312 10,085 Warrant liabilitisi 10,312 10,085 Contingent consideration — 4,907 Long-term debt, net 89,824 108,319 Other Long-Term Liabilities 26,001 — TOTAL LIABILITIES ⁽¹⁾ 633,891 427,305 COMMITMENTS AND CONTINGENCIES (Note 13) 633,891 427,305 MEZZANINE EQUITY: 73,593 291,532 Redeemable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: 16 12 Class A common stock, \$0,0001 par value; 200,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Additional paid in capital 570,093 509,442 200 20 20 20 20 20 20 20 <td>Accrued interest</td> <td></td> <td>12,460</td> <td>23,648</td>	Accrued interest		12,460	23,648
TOTAL CURRENT LIABILITIES496,415299,372Operating lease liability11,33913,622Warrant liabilities10,3121,085Contingent consideration—4,907Long-term debt, net89,824108,319Other Long-Term Liabilities26,001—TOTAL LIABILITIES ⁽¹⁾ 633,891427,305COMINTENTS AND CONTINGENCIES (Note 13)——MEZZANINE EQUITY:———Class A common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively1612Class A common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively1612Additional paid in capital——2020Additional paid in capital——142,130TOTAL STOCKHOLDERS' EQUITY——142,130TOTAL STOCKHOLDERS' EQUITY——142,130	Current portion of long-term debt		65,000	_
Operating lease liability 11,339 13,622 Warrant liabilities 10,312 1,085 Contingent consideration — 4,907 Long-term debt, net 88,824 108,319 Other Long Term Liabilities 26,001 — TOTAL LIABILITIES ⁽¹⁾ 633,891 427,305 COMMITMENTS AND CONTINGENCIES (Note 13) — — MEZZANINE EQUITY: — — Redeenable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: — — Class A common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class A common stock, \$0,0001 par value; 205,000 shares authorized; 162,870 and 116,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Additional paid in capital — — 20 20 Additional paid in capital	Liabilities held for sale		353	_
Warrant liabilities 10,312 1,085 Contingent consideration — 4,907 Long-term deb, net 89,824 108,319 Other Long-Term Liabilities 26,001 — TOTAL LIABILITIES ⁽¹⁾ 633,891 427,305 COMITIMENTS AND CONTINGENCIES (Note 13) — — MEZZANINE EQUITY: — — Redeemable non-controlling interest 73,593 221,532 STOCKHOLDERS' EQUITY: — — Class A common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 112 Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Additional pail in capital — — 10 12 Accumulated deficit	TOTAL CURRENT LIABILITIES		496,415	 299,372
Contingent consideration–4,907Long-term debt, net89,824108,319Other Long-Term Liabilities26,001–TOTAL LIABILITIES ⁽¹⁾ 633,891427,305COMMITMENTS AND CONTINGENCIES (Note 13)633,891427,305MEZZANINE EQUITY:73,593291,532STOCKHOLDERS' EQUITY:73,593291,532Class A common stock, \$0,0001 par value; 200,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively1612Class A common stock, \$0,0001 par value; 200,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively2020Additional paid in capital579,093509,442579,093509,442Accumulated deficit(503,193)(367,344)172,936142,130TOTAL STOCKHOLDERS' EQUITY75,936142,130142,130	Operating lease liability		11,339	13,622
Long-term debt, net 89,824 108,319 Other Long-Term Liabilities 26,001 — TOTAL LIABILITIES ⁽¹⁾ 633,891 427,305 COMMITMENTS AND CONTINGENCIES (Note 13) MEZZANINE EQUITY:	Warrant liabilities		10,312	1,085
Other Long-Term Liabilities 26,001 TOTAL LIABILITIES ⁽¹⁾ 633,891 427,305 COMITIMENTS AND CONTINGENCIES (Note 13) MEZZANINE EQUITY: Redeenable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: Class A common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class A common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Additional paid in capital 579,093 509,442 Accumulated deficit (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	Contingent consideration		-	4,907
TOTAL LIABILITIES ⁽¹⁾ 633,891 427,305 COMMITMENTS AND CONTINGENCIES (Note 13) 633,891 427,305 MEZZANINE EQUITY: 73,593 291,532 Redeemable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: 16 12 Class A common stock, \$0,0001 par value; 200,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Additional paid in capital 579,093 509,442 20 20 Additional paid in capital (503,193) (367,344) (367,344) 142,130 TOTAL STOCKHOLDERS' EQUITY 175,936 142,130 142,130 142,130	Long-term debt, net		89,824	108,319
COMMITMENTS AND CONTINGENCIES (Note 13) MEZZANINE EQUITY: Redemable non-controlling interest STOCKHOLDERS' EQUITY: Class A common stock, \$0.0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$0.0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Additional paid in capital 579,093 509,442 Accumulated deficit (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	Other Long-Term Liabilities		26,001	
MEZZANINE EQUITY: Redeemable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: Class A common stock, \$0,0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Additional paid in capital 579,093 509,442 Accumulated deficit 10 (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY	TOTAL LIABILITIES ⁽¹⁾		633,891	427,305
Redeemable non-controlling interest 73,593 291,532 STOCKHOLDERS' EQUITY: 16 12 Class A common stock, \$00,000 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$00,000 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Additional paid in capital 579,093 509,442 Accumulated deficit (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	COMMITMENTS AND CONTINGENCIES (Note 13)			
STOCKHOLDERS' EQUITY: Class A common stock, \$0,000 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively Additional paid in capital Accumulated deficit TOTAL STOCKHOLDERS' EQUITY Class V common stock, \$0,0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 20 20 20 20 20 20 20 20	MEZZANINE EQUITY:			
Class A common stock, \$0.0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively 16 12 Class V common stock, \$0.0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Additional paid in capital 579,093 509,442 Accumulated deficit (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	Redeemable non-controlling interest		73,593	291,532
Class V common stock, \$0.0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively 20 20 Additional paid in capital 579,093 509,442 579,093 509,442 Accumulated deficit (503,193) (367,344) 130 142,130 TOTAL STOCKHOLDERS' EQUITY 75,936 142,130 142,130	STOCKHOLDERS' EQUITY:			
Additional paid in capital 579,093 509,442 Accumulated deficit (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	Class A common stock, \$0.0001 par value; 800,000 shares authorized; 162,870 and 116,588 shares issued and outstanding as of December 31, 2024 and 2023, respectively		16	12
Accumulated deficit (503,193) (367,344) TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	Class V common stock, \$0.0001 par value; 205,000 shares authorized; 195,957 and 196,569 shares issued and outstanding as of December 31, 2024 and 2023, respectively		20	20
TOTAL STOCKHOLDERS' EQUITY 75,936 142,130	Additional paid in capital		579,093	509,442
	Accumulated deficit	_	(503,193)	 (367,344)
TOTAL LIABILITIES, MEZZANINE EOUITY, AND STOCKHOLDERS' EOUITY \$ 783,420 \$ 860,967	TOTAL STOCKHOLDERS' EQUITY		75,936	 142,130
	TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY	\$	783,420	\$ 860,967

(1) The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). As discussed in Note 20 "Variable Interest Entities," P3 LLC is itself a VIE, P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC's consolidated VIEs totaling \$9.3 million and \$8.6 million as of December 31, 2024 and 2023, respectively, and total liabilities of P3 LLC's consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled \$14.9 million and \$13.6 million aof December 31, 2024 and 2023, respectively, as these are eliminated in consolidation and not presented within the consolidated balance sheets.

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited)

	Three Months En	ded December 31,	Year Ended December 31,				
	2024	2023	2024	2023			
OPERATING REVENUE:							
Capitated revenue \$	367,456	\$ 342,836	\$ 1,483,602	\$ 1,252,309			
Other patient service revenue	3,230	4,025	16,853	14,066			
TOTAL OPERATING REVENUE	370,686	346,861	1,500,455	1,266,375			
OPERATING EXPENSE:							
Medical expense	410,224	367,679	1,559,372	1,234,740			
Premium deficiency reserve	37,927	(3,344)	53,698	(12,705)			
Corporate, general and administrative expense	31,366	24,431	112,596	122,362			
Sales and marketing expense	461	721	1,331	3,233			
Depreciation and amortization	21,153	21,634	86,058	86,675			
Impairment of Assets Held for Sale	8,058	—	8,058	—			
TOTAL OPERATING EXPENSE	509,189	411,121	1,821,113	1,434,305			
OPERATING LOSS	(138,503)	(64,260)	(320,658)	(167,930)			
OTHER INCOME (EXPENSE):							
Interest expense, net	(6,834)	(4,046)	(22,173)	(15,985)			
Mark-to-market of stock warrants	7,488	760	22,114	433			
Other	384	206	1,457	(249)			
Gain on asset sale, net	13,269	_	13,269	_			
TOTAL OTHER (EXPENSE) INCOME	14,307	(3,080)	14,667	(15,801)			
LOSS BEFORE INCOME TAXES	(124,196)	(67,340)	(305,991)	(183,731)			
PROVISION FOR INCOME TAXES	(4,952)	(1,767)	(4,387)	(2,695)			
- NET LOSS	(129,148)	(69,107)	(310,378)	(186,426)			
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST	(70,531)	(43,645)	(174,529)	(128,653)			
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST \$							
NET LOSS PER SHARE (Note 16):							
Basic	(0.36)	(0.22)	(0.94)	(0.61)			
Diluted	(0.36)	(0.22)	(1.08)	(0.63)			
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 16):							
Basic	162,634	115,303	145,175	94,889			
Diluted	162,634	115,303	146,998	294,590			

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

	Year Ended Decer	nber 31,
	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (310,378) \$	(186,42
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	86,058	86,67
Equity-based compensation	5,752	5,97
Amortization of original issue discount and debt issuance costs	87	47
Accretion of contingent consideration	—	11:
Gain on write off of contingent consideration	(4,907)	_
Gain on asset sale	(13,269)	_
Deferred income taxes	(1,090)	_
Impairment of assets held for sale	8,058	—
Mark-to-market adjustment of stock warrants	(22,114)	(43)
Premium deficiency reserve	53,698	(12,705
Changes in operating assets and liabilities:		
Health plan receivable	(2,769)	(46,55
Clinic fees, insurance, and other receivable	(990)	4,560
Prepaid expenses and other current assets	(10,834)	(1,24)
Other long-term assets	(43)	(5)
Accounts payable, accrued expenses, and other current liabilities	(8,101)	15,98
Accrued payroll	(784)	28
Health plan settlements payable	20,573	21,38
Claims payable	77,080	26,80
Accrued interest	7,895	9,58
Other long-term liabilities	5,897	_
Operating lease liability	53	(450
Net cash used in operating activities	(110,128)	(76,028
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	_	(1,82
Proceeds from asset sale	14,525	-
Net cash provided by (used in) investing activities	14,525	(1,82)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from long-term debt, net of original issue discount	88,057	14,10
Payment of debt issuance costs	(103)	(17)
Proceeds from liability-classified warrants and private placement offering, net of offering costs paid	40,496	86,59
Proceeds from at-the-market sales, net of offering costs paid	33	_
Deferred offering costs paid	(507)	(175
Payment of tax withholdings upon settlement of restricted stock unit awards	(103)	(10
Repayment of short-term and long-term debt	(30,973)	_
Proceeds from short-term debt	1,871	_
Net cash provided by financing activities	98,771	100,33
Net change in cash and restricted cash	3,168	22,47
Cash and restricted cash, beginning of year	40,934	18,45
	\$ 44,102 \$	40,934
Cash and restricted cash, end of year	\$ 44,102 \$	40,934

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) *(in thousands)*

Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes\$(22,831)\$(11)Fair value adjustment to redeemable noncontrolling interest\$(20,579)\$2Warrants issued in connection with new debt\$12,127\$Reconciliation of cash and restricted cash:		Year Ended	ıber 31,	
Cash paid for interest§14,191§Cash paid for income taxes§5,477\$Supplemental disclosures of non-cash investing and financing information:S617\$Operating lease liabilities arising from obtaining new right-of-use assets\$617\$Operating lease liabilities and right-of-use assets reduced due to lease modification or termination\$92\$Increase in accrued expenses related to debt issuance costs and original issue discount\$307\$Increase in accounts payable related to private placement offering costs\$686\$Increase in accrued expenses related to at-the-market offering costs\$\$\$Increase in accrued expenses related to at-the-market offering costs\$\$\$Increase in other receivable related to at-the-market offering costs\$\$\$Increase in other receivable related to at-the-market sales proceeds\$\$\$Restricted stock unit awards issued in satisfaction of executive transaction bonuses\$\$\$Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes\$\$\$Warrants issued in connection with new debt\$\$\$\$Reconciliation of cash and restricted cash:\$\$\$\$		2024		2023
Cash paid for income taxes \$ 5,477 \$ Supplemental disclosures of non-cash investing and financing information: • • Operating lease liabilities arising from obtaining new right-of-use assets \$ 617 \$ Operating lease liabilities and right-of-use assets reduced due to lease modification or termination \$ 092) \$ Increase in accrued expenses related to debt issuance costs and original issue discount \$ 3007 \$ Increase in accounts payable related to private placement offering costs \$ 686 \$ \$ Increase in accounts payable related to at-the-market offering costs \$ - \$ \$ \$ \$ Increase in accurued expenses related to at-the-market offering costs \$ - \$ <	Supplemental disclosures of cash flow information:			
Supplemental disclosures of non-cash investing and financing information: Operating lease liabilities arising from obtaining new right-of-use assets Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced due to lease modification or termination S Operating lease liabilities and right-of-use assets reduced and right of the market offering costs S S	Cash paid for interest	\$ 14,191	\$	5,813
Operating lease liabilities arising from obtaining new right-of-use assets\$617\$Operating lease liabilities and right-of-use assets reduced due to lease modification or termination\$(92)\$Increase in accrued expenses related to debt issuance costs and original issue discount\$307\$Increase in accounts payable related to private placement offering costs\$686\$Increase in accounts payable related to at-the-market offering costs\$\$\$Increase in accounts payable related to at-the-market offering costs\$\$\$Increase in accounts payable related to at-the-market offering costs\$\$\$Increase in other receivable related to at-the-market sales proceeds\$\$\$Restricted stock unit awards issued in satisfaction of executive transaction bonuses\$\$\$\$Remeasurement adjustment to redeemable noncontrolling interest\$\$\$\$\$Warrants issued in connection with new debt\$\$\$\$\$\$Reconciliation of cash and restricted cash:\$\$\$\$\$\$	Cash paid for income taxes	\$ 5,477	\$	567
Operating lease liabilities and right-of-use assets reduced due to lease modification or termination\$(92)\$Increase in accrued expenses related to debt issuance costs and original issue discount\$307\$Increase in accounts payable related to private placement offering costs\$686\$Increase in accounts payable related to at-the-market offering costs\$\$\$Increase in accrued expenses related to at-the-market offering costs\$\$\$Increase in accrued expenses related to at-the-market offering costs\$\$\$Increase in other receivable related to at-the-market sales proceeds\$\$\$Restricted stock unit awards issued in satisfaction of executive transaction bonuses\$\$\$Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes\$\$\$Varrants issued in connection with new debt\$\$12,127\$Reconciliation of cash and restricted cash:\$\$\$\$	Supplemental disclosures of non-cash investing and financing information:			
Increase in accrued expenses related to debt issuance costs and original issue discount \$ 307 \$ Increase in accounts payable related to private placement offering costs \$ 686 \$ Increase in accounts payable related to at-the-market offering costs \$ 686 \$ Increase in accounts payable related to at-the-market offering costs \$ \$ \$ Increase in accrued expenses related to at-the-market offering costs \$ \$ \$ Increase in other receivable related to at-the-market sales proceeds \$ \$ \$ Restricted stock unit awards issued in satisfaction of executive transaction bonuses \$ \$ \$ Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes \$ \$ \$ \$ Varrants issued in connection with new debt \$	Operating lease liabilities arising from obtaining new right-of-use assets	\$ 617	\$	7,222
Increase in accounts payable related to private placement offering costs\$686Increase in accounts payable related to at-the-market offering costs\$\$Increase in accounts payable related to at-the-market offering costs\$\$Increase in accrued expenses related to at-the-market offering costs\$\$Increase in other receivable related to at-the-market sales proceeds\$\$Restricted stock unit awards issued in satisfaction of executive transaction bonuses\$\$Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes\$\$Yarrants issued in connection with new debt\$\$\$Reconciliation of cash and restricted cash:\$\$\$	Operating lease liabilities and right-of-use assets reduced due to lease modification or termination	\$ (92)	\$	_
Increase in accounts payable related to at-the-market offering costs \$ - \$ \$ 1 \$ \$ 1 \$	Increase in accrued expenses related to debt issuance costs and original issue discount	\$ 307	\$	212
Increase in accrued expenses related to at-the-market offering costs \$	Increase in accounts payable related to private placement offering costs	\$ 686	\$	12
Increase in other receivable related to at-the-market sales proceeds \$ - \$ Restricted stock unit awards issued in satisfaction of executive transaction bonuses \$ - \$ Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes \$ (22,831) \$ (11) Fair value adjustment to redeemable noncontrolling interest \$ (20,579) \$ 2 Warrants issued in connection with new debt \$ 12,127 \$ 2 Reconciliation of cash and restricted cash: - - - -	Increase in accounts payable related to at-the-market offering costs	\$ —	\$	19
Restricted stock unit awards issued in satisfaction of executive transaction bonuses \$ - \$ Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes \$ (22,831) \$ (11) Fair value adjustment to redeemable noncontrolling interest \$ (20,579) \$ 2 Warrants issued in connection with new debt \$ 12,127 \$ \$	Increase in accrued expenses related to at-the-market offering costs	\$ _	\$	206
Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes \$ (22,831) \$ (11) Fair value adjustment to redeemable noncontrolling interest \$ (20,579) \$ (21) Warrants issued in connection with new debt \$ 12,127 \$	Increase in other receivable related to at-the-market sales proceeds	\$ —	\$	33
Fair value adjustment to redeemable noncontrolling interest \$ (20,579) \$ 2 Warrants issued in connection with new debt \$ 12,127 \$ Reconciliation of cash and restricted cash: \$ 12,127 \$	Restricted stock unit awards issued in satisfaction of executive transaction bonuses	\$ 	\$	5,000
Warrants issued in connection with new debt \$ 12,127 \$ Reconciliation of cash and restricted cash: \$ \$	Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes	\$ (22,831)	\$	(117,860)
Reconciliation of cash and restricted cash:	Fair value adjustment to redeemable noncontrolling interest	\$ (20,579)	\$	20,579
	Warrants issued in connection with new debt	\$ 12,127	\$	_
Cash \$ 38,816 \$	Reconciliation of cash and restricted cash:			
	Cash	\$ 38,816	\$	36,320
Restricted cash 5,286	Restricted cash	 5,286		4,614
Total cash and restricted cash\$44,102\$4	Total cash and restricted cash	\$ 44,102	\$	40,934

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA LOSS

(in thousands, except PMPM)

(unaudited)

	Three Months Ended December 31,			Year Ended	December 31,	
	2024		2023	2024		2023
Net loss	\$ (129,148)	\$	(69,107)	\$ (310,378)	\$	(186,426)
Interest expense, net	6,834		4,046	22,173		15,985
Depreciation and amortization	21,153		21,634	86,058		86,675
Income tax provision	4,952		1,767	4,387		2,695
Mark-to-market of stock warrants	(7,488)		(760)	(22,114)		(433)
Premium deficiency reserve	37,927		(3,344)	53,698		(12,705)
Equity-based compensation	721		1,720	5,752		5,979
Other ⁽¹⁾	(2,533)		(212)	(6,775)		2,656
Transaction and other related costs ⁽²⁾	—		—	—		70
Adjusted EBITDA loss	\$ (67,582)	\$	(44,256)	\$ (167,199)	\$	(85,504)
Adjusted EBITDA loss PMPM	\$ (175)	\$	(138)	\$ (147)	\$	(92)

(1) Other during the year ended December 31, 2024 consisted of (i) interest income, (ii) gain recognized upon the settlement and write-off of contingent consideration related to an acquisition completed in a prior year and (iii) gain recognized on asset sale partially offset by (iv) severance and related expense in connection with our chief executive officer transition (v) loss on impairment on assets held for sale, and (vi) valuation allowance on our notes receivable. Other during the year ended December 31, 2023 consisted of (i) interest income offset by (ii) cybersecurity incident loss, (iii) restructuring and other charges, including severance and benefits paid to employees pursuant to workforce reduction plans, (iv) the disposition of our Pahrump operations, (v) expenses for third-party consultants to assist us with the development, implementation, and documentation of new and enhanced internal controls and processes for compliance with Sarbanes-Oxley Section 404(b), (vi) a legal settlement outside of the ordinary course of business, and (vii) valuation allowance on our notes receivable.

(2) Transaction and other related costs during the year ended December 31, 2023 consisted of legal fees incurred related to acquisition-related litigation.

MEDICAL MARGIN (in thousands, except PMPM)

(unaudited)

	Three Months Ended December 31,				Year Ended December 31,			
	2024		2023		2024		2023	
Capitated revenue	\$ 367,456	\$	342,836	\$	1,483,602	\$	1,252,309	
Less: medical claims expense	(360,178)		(333,761)		(1,398,143)		(1,117,258)	
Medical margin	\$ 7,278	\$	9,075	\$	85,459	\$	135,051	
Medical margin PMPM	\$ 19	\$	28	\$	75	\$	108	

RECONCILIATION OF GROSS PROFIT (LOSS) TO MEDICAL MARGIN (in thousands)

	Three Months Ended December 31,				Year Ended December 31,			
	2024		2023		2024		2023	
Gross profit (loss)	\$ (39,538)	\$	(20,818)	\$	(58,917)	\$	31,635	
Other patient service revenue	(3,230)		(4,025)		(16,853)		(14,066)	
Other medical expense	50,046		33,918		161,229		117,482	
Medical margin	\$ 7,278	\$	9,075	\$	85,459	\$	135,051	

RECONCILIATION OF TOTAL OPERATING EXPENSE TO ADJUSTED OPERATING EXPENSE (in thousands) (unaudited)

	Three Months Ended December 31,				Year Ended December 31,					
	2024		2023		2024		2023			
Total operating expense	\$ 509,189	\$	411,121	\$	1,821,113	\$	1,434,305			
Medical expense	(410,224)		(367,679)		(1,559,372)		(1,234,740)			
Depreciation and amortization	(21,153)		(21,634)		(86,058)		(86,675)			
Premium deficiency reserve	(37,927)		3,344		(53,698)		12,705			
Equity-based compensation	(721)		(1,720)		(5,752)		(5,979)			
Other	2,533		212		6,775		(2,656)			
Transaction and other related costs	—		—		—		(70)			
Adjusted operating expense	\$ 41,697	\$	23,644	\$	123,008	\$	116,890			